top of page

X4 Pharma's CEO on the recent launch of XOLREMDI for WHIM Syndrome and CXCR4 inhibition more broadly for additional indications

  • blonca9
  • Jun 7, 2024
  • 1 min read

Paula Ragan describes the launch of this medicine that was approved at the end of April and previews an upcoming data announcement X4 will have in chronic neutropenia towards the end of the month.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page